Wordt geladen...

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

PURPOSE: Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Oncol
Hoofdauteurs: Shah, Nirali N., Highfill, Steven L., Shalabi, Haneen, Yates, Bonnie, Jin, Jianjian, Wolters, Pamela L., Ombrello, Amanda, Steinberg, Seth M., Martin, Staci, Delbrook, Cindy, Hoffman, Leah, Little, Lauren, Ponduri, Anusha, Qin, Haiying, Qureshi, Haris, Dulau-Florea, Alina, Salem, Dalia, Wang, Hao-Wei, Yuan, Constance, Stetler-Stevenson, Maryalice, Panch, Sandhya, Tran, Minh, Mackall, Crystal L., Stroncek, David F., Fry, Terry J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2020
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280047/
https://ncbi.nlm.nih.gov/pubmed/32286905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.03279
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!